Crescita Therpeutc (TSE:CTX) has released an update.
Crescita Therapeutics reported a revenue increase of 18.5% in Q3 2024, driven by growth in its Skincare segment and higher licensing revenue. The company is also enhancing its manufacturing capabilities with new equipment and a long-term agreement with a major client, aiming to boost profitability and secure a new partner for Pliaglis in the U.S.
For further insights into TSE:CTX stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Phillip Securities Analyst Lifts Meta Price Target on Solid AI Potential
- Insider Trade: Carvana CFO Accumulates Shares Worth $37.7M
- 3 Penny Stocks to Watch Now, 11/7/24
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
